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Abstract
Objective—To assess the effects of supervised and home-based aerobic exercise training, and 
antidepressant pharmacotherapy (sertraline) on coronary heart disease (CHD) risk factors in a 
sample of participants with major depressive disorder (MDD).
Methods—The SMILE-II study randomized 202 adults (153 women; 49 men) diagnosed with 
MDD to one of four interventions, each of 4 months duration: supervised exercise; home-based 
exercise; antidepressant medication (sertraline, 50–200 mg daily); or placebo pill. Patients 
underwent a structured clinical interview for depression and completed the Hamilton Depression 
Rating Scale (HAM-D). CHD risk factors included brachial artery flow-mediated dilation (FMD), 
carotid intima-media thickness (IMT), serum lipids, and 10-year Atherosclerotic Cardiovascular 
Disease (ASCVD) risk.
Results—Compared to placebo, active treatment for depression (supervised exercise, home-
based exercise, sertraline therapy) was associated with an improvement in CHD risk factors 
(improved FMD (P=.032), reduced progression of IMT (P=.037), and a reduction in 10-year 
ASCVD (P=.049)). The active treatments did not differ from each other in their effects on the 
CHD risk outcomes.
Conclusions—Both exercise and antidepressant medication improved CHD risk factors and 
lowered ASCVD risk in patients with MDD. Because MDD is associated with increased risk for 
CHD events, treatment of depression with exercise or sertraline may reduce the risk of developing 
CHD in patients with MDD.
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INTRODUCTION
The presence of depression in otherwise healthy individuals confers about a 1.5 to 2.0-fold 
adjusted relative risk for the subsequent development of coronary artery disease (1–4) and is 
prospectively associated with a 2- to 4-fold higher relative risk for cardiac mortality (5) and 
non-fatal acute myocardial infarction (3). In patients with established coronary heart disease 
(CHD), depression is associated with a 2 to 4-fold increased risk for adverse cardiac events, 
including fatal and non-fatal myocardial infarction (MI) and all-cause mortality(6–9) In a 
comprehensive review of the extant literature, the American Heart Association Scientific 
Advisory Panel recently recommended that depression be considered a risk factor for 
patients with CHD (10). Despite the clinical relevance of depression in healthy adults and in 
patients with established CHD, the value of treating depression in cardiac patients has 
produced mixed results. The ENRICHD trial reported modest improvements in depressive 
symptoms relative to usual care controls in a sample of over 2500 post-myocardial infarction 
patients, but there was no survival benefit (11). The SADHART trial found that CHD 
patients with MDD randomized to sertraline had greater reductions in depressive symptoms 
compared to placebo controls, but only in a subgroup of patients with more severe MDD 
(12). However, in a study of depressed heart failure patients, sertraline did not perform any 
better than placebo, and there was no survival advantage for sertraline compared to placebo 
(13).
Recently, exercise training has received widespread attention for successfully treating 
depression in otherwise healthy individuals with MDD (14–17) and in patients with stable 
CHD (18) and heart failure (19). Exercise also may improve clinical outcomes in patients 
with depression. For example, a post hoc analysis of the ENRICHD trial revealed that 
patients who exercised during the 6-months following their myocardial infarctions not only 
had reduced depression but also had a 50% improvement in all-cause mortality risk (20). 
Similarly, the HF-ACTION trial reported that exercise reduced depressive symptoms and 
improved survival (19, 21). The SMILE-II study was a randomized clinical trial comparing 
exercise and sertraline to placebo in a sample of 202 outpatients with MDD without 
documented CHD. Primary results of the trial, which showed significant and comparable 
improvements in depression for exercise and sertraline relative to placebo controls, have 
been previously reported (16).
The present report describes the effects of exercise and sertraline on CHD risk factors in this 
sample of adults with MDD without known CHD. Two specific risk factors related to 
subclinical atherosclerosis were examined: brachial artery flow-mediated dilation (FMD), 
and carotid artery intima-media thickness (IMT), both of which are prognostic of adverse 
cardiovascular outcomes (22, 23). In addition, we assessed intervention effects on the 
estimated 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk using the recently 
developed Pooled Cohort Equations (24). We hypothesized that both exercise and sertraline 
would result in improved CHD risk compared to placebo controls, and that exercise would 
produce greater reductions in subclinical atherosclerosis compared to sertraline.
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METHODS
Experimental Design
As described in our initial report (9) participants were recruited between October 2000 and 
November 2005. In addition to the presence of MDD, eligibility criteria included age ≥40 
years, not currently exercising, and no current psychiatric treatment. Exclusion criteria 
included the presence of another primary psychiatric diagnosis, such as a history of bipolar 
disorder or psychosis; and medical comorbidities that would preclude participation in the 
trial. All participants provided written informed consent and the protocol was approved by 
the Institutional Review Board at Duke University Medical Center. This study was a 
randomized, parallel group, placebo-controlled trial of exercise (group-supervised and 
individual home-based), and sertraline treatment for MDD. CHD biomarker data were 
collected before and following 4 months of treatment.
Treatment Groups
Participants were assigned randomly in equal proportions to a 4-month intervention of 
supervised aerobic exercise (n =51), home-based aerobic exercise (n = 53), sertraline (n = 
49), or placebo (n = 49). Randomization was performed centrally by computer with 
conditional randomization (stratified by age, sex, and depression severity).
Exercise Conditions—Patients in the Supervised Aerobic Exercise condition attended 
three supervised group exercise sessions per week and exercised at 70% to 85% maximum 
heart rate reserve for 30 minutes of walking or jogging on a treadmill. Participants in the 
Home-based Exercise program received the same individualized exercise prescription but 
exercised at home, on their own, with minimal staff contact; participants received visits from 
an exercise physiologist after 1 month and 2 months, and brief weekly telephone calls for the 
first month and biweekly thereafter until the end of the 16-week trial.
Pill Conditions—Participants in the “pill” conditions were given sertraline, or matching 
placebo, provided by Pfizer, Inc. The dosage depended on the clinical response, but usually 
each patient received a starting dose of 50 mg (one pill) daily with increasing doses up to 
200 mg (four pills) daily, based on therapeutic response and presence of side effects. The 
treating psychiatrist was blinded to pill condition and used supportive measures to help 
manage medication side effects.
Aerobic Fitness
Exercise-Treadmill Testing—Graded treadmill exercise testing was conducted before 
and after the 4-month treatment program to: a) establish an initial exercise prescription for 
participants randomized to exercise, and; b) to document changes in patients’ aerobic fitness. 
Patients exercised to exhaustion under continuous electrocardiographic monitoring in which 
workloads were increased at a rate of 1 metabolic equivalent/min (25). Expired gases were 
analyzed by a Parvo Medics True One measurement system (Parvo Medics, Sandy, Utah). 
Peak VO2 served as the primary measure of aerobic fitness.
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CHD Risk Assessments
Flow Mediated Dilation (FMD) of the Brachial Artery—FMD of the brachial artery 
was assessed in the morning, after overnight fasting. Longitudinal B-mode ultrasound 
images of the brachial artery, 4 to 6 cm proximal to the antecubital crease, were obtained 
using an ultrasound platform (Aspen, Mountain View, CA) with a 10-MHz linear array 
transducer. Images were obtained after 10 minutes of supine relaxation and during reactive 
hyperemia, induced by 5 minutes of inflation of a pneumatic occlusion cuff placed around 
the forearm to a supra-systolic pressure (≥200 mm Hg). End-diastolic images were stored to 
a magnetic-optical disk and arterial diameters were measured as the distance between the 
proximal and distal arterial wall intima-media interfaces, using PC-based software (Brachial 
Analyzer Version 4.0, Medical Imaging Applications LLC, Iowa City, IA). Peak FMD 
response was assessed from 10 to 120 seconds post deflation of the cuff, with peak arterial 
diameter quantified using polynomial curve fitting. FMD was defined as the maximum 
percent change in arterial diameter relative to resting baseline
Intima Medial Thickness (IMT) in Carotid Arteries—Carotid artery IMT was 
assessed by a high-resolution B-mode ultrasound vascular imaging system (Acuson Aspen, 
Mountain View, CA) with a 10-Mhz linear array transducer. Ultrasound examinations of the 
far wall of the left and right common carotid arteries (CCAs) were used to acquire 
longitudinal images spanning 2 cm proximal to the carotid bulb. IMT of the far wall of the 
left and right CCAs was measured over a 1-cm segment using edge detection software 
(Carotid Analyzer 5.0.5, Medical Imaging Applications LLC, Iowa City, IA).
Atherosclerotic Disease Risk Scores—Cardiovascular risk scores were calculated 
using the Pooled Cohort Risk Assessment Equations recently developed by the American 
College of Cardiology/American Heart Association Risk Assessment Work Group (24). 
These equations quantify the 10-year risk of Atherosclerotic Cardiovascular Disease 
(ASCVD), defined as nonfatal myocardial infarction, coronary heart disease death, or fatal 
or non-fatal stroke. Scores are determined based on risk algorithms using systolic blood 
pressure, use of antihypertensive therapy, diabetes mellitus, cigarette smoking, total 
cholesterol, and high density lipoprotein (HDL) cholesterol. Blood pressure was measured 
by a Physician’s Assistant during a history and physical examination that also was the basis 
for determining medication use and presence of diabetes. The average of two seated blood 
pressure measurements was used in the present analyses. Blood samples were obtained 
following an overnight fast. Total cholesterol, HDL cholesterol and low-density lipoprotein 
(LDL) cholesterol were measured enzymatically (LabCorp, Burlington, NC). HDL 
cholesterol was determined by assay of the supernatant remaining after precipitation of 
serum LDL with dextran sulfate plus magnesium chloride. Risk scores are determined 
separately by sex and ethnicity (Caucasian or African-American). For the purposes of the 
present analyses, the ASCVD scores for all minority participants were determined using risk 
algorithms for African-Americans.
Statistical Analysis
Treatment group effects for CHD risk factors were evaluated using general linear models 
through SAS 9.2 (PROC GLM, SAS Institute, Cary, NC). For our primary analysis of 
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changes in CHD risk factors, a rank-based composite was created combining IMT, FMD, 
and CVD risk scores. The composite measure was created by ranking each individual on 
each biomarker at baseline and following treatment. A mean rank score was then created by 
averaging across all CHD risk markers at pre-treatment and at post-treatment. At each time-
point the mean rank was then standardized using a midrank specification (i.e. mean rank 
divided by sample size plus one). The post-treatment midrank was the outcome variable in 
our primary analysis (26). Analysis of treatment effects followed the intention-to-treat (ITT) 
principle, with post-treatment missing data managed using Markov chain Monte Carlo 
multiple imputation methods available in SAS (PROC MI) and 150 imputations. After 
examining change in the composite measure, we conducted follow-up analyses of each CHD 
risk marker individually. The ASCVD risk score was found to be significantly skewed and 
was therefore rank-transformed prior to analysis, whereas no transformation was required 
for either IMT or FMD. Improvements in depression were examined using a logistic model 
in which post-treatment remission (defined as no longer meeting criteria for MDD and 
achieving a HAM-D rating of < 8) was modeled as the outcome of interest (PROC 
GENMOD). As reported in our primary paper, we eliminated individual “early responders” 
and considered individuals without post-treatment depression as remitted (16). Within all 
models we controlled baseline randomization stratification factors (age, sex, pretreatment 
depression severity (HAM-D≥18), and the respective pre-treatment level of each outcome 
variable. We also controlled for baseline arterial diameter in our analyses of FMD. Planned, 
orthogonal contrasts were conducted comparing all three active treatment groups vs. 
placebo, the two exercise groups vs. sertraline, and the supervised and home-based exercise 
programs. We evaluated the extent to which models met assumptions, including additivity, 
linearity, and distribution of residuals. We found no evidence of significant violations of 
these assumptions.
RESULTS
Participants
Four hundred fifty-seven participants were screened, of whom 202 were randomized. 
Among individuals who were excluded (n = 255), 135 did not meet inclusion criteria, 47 
withdrew consent, 40 had significant psychiatric comorbidities, 13 had contraindications to 
exercise, 15 had poor assessment adherence, 3 individuals had contraindications to 
Sertraline, one participant was already exercising, and one was actively involved in 
psychiatric treatment. Participants were generally middle-aged and Caucasian, with 
relatively few CHD risk factors. Few participants were taking either antihypertensive or lipid 
lowering medications. Treatment groups did not differ in any background CHD risk factor 
characteristics at baseline (see Table 1).
Adherence and Treatment Fidelity
Thirty-four participants dropped out during the course of the trial (3 in home-based exercise, 
10 in supervised exercise, 7 in sertraline, and 14 in Placebo). Dropouts did not differ from 
completers on any clinical or demographic characteristics, or in pre-treatment CHD 
biomarker levels. As reported in the primary paper, adherence to medication was evaluated 
by pill count and was excellent for sertraline and placebo groups, with an average of 89% 
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(SD = 24.6) pill adherence in the sertraline group and 88% (SD = 29.6) in the placebo group. 
When dropouts were eliminated, adherence was 95% (SD = 8.4) in the sertraline group and 
97% (SD = 8.1) in the placebo group.
Exercise adherence also was excellent, with supervised and home-based exercisers 
completing 70% and 79% of scheduled sessions, respectively, excluding dropouts. 
Individuals in the home-based exercise group reported exercising in more sessions compared 
with supervised exercise (36.9 [14.1] vs. 28.5 [15.5], P = .005). However, the supervised 
group exhibited higher average heart rates (138.6 beats per minute [SD = 12.1]) during 
exercise sessions and reported higher ratings of perceived exertion (13.4 [SD = 1.4]) relative 
to the home-based group (131.6 beats per minute [SD = 16.9], 12.8 [1.5]; P = .025, P = .091, 
respectively).
Cardiopulmonary Training Effects
As previously reported (16), greater improvements in peak oxygen consumption (peak VO2) 
were observed in the active treatment groups compared to the placebo group (P < .001) and 
the exercise groups exhibited larger improvements compared to the sertraline group (P < .
001). A similar pattern of results was noted for exercise treadmill duration, with the 
supervised exercise (1.8 minutes [1.4, 2.3]) and home-based exercise (0.9 minutes [0.4, 1.3]) 
groups showing the greatest improvements, whereas the sertraline (−0.20 minutes [−0.6, 
0.3]) and placebo (−0.32 minutes [−0.8, 0.2]) groups showed slight decreases in treadmill 
time.
CHD Risk Changes
Examination of treatment changes in CHD risk factors revealed that the three active 
treatment groups showed greater improvements on the composite measure of CHD risk 
compared to placebo (P = .001), whereas the exercise and sertraline groups did not differ 
from each other (P = .896) (Table 2). Specifically, the supervised exercise group (post-
treatment midrank 0.52 [0.48, 0.55]) and sertraline group (post-treatment midrank 0.52 
[0.48, 0.55]) demonstrated the greatest improvements on our composite CHD biomarker 
measure, followed by the home-based exercise group (post-treatment midrank 0.47 [0.44, 
0.51]) and placebo group (post-treatment midrank 0.44 [0.42, 0.48]). Having established 
evidence of an overall treatment effect, we proceeded to examine the component measures 
comprising the composite CHD biomarker.
Flow Mediated Dilation—Examination of treatment changes showed that the active 
treatment groups exhibited greater improvements in FMD over the course of the intervention 
compared with placebo participants FMD (P = .032). The exercise and sertraline groups did 
not differ from one another (P = .798). Examination of changes in FMD showed that the 
supervised exercise (1.02% [−0.15, 2.20]) and sertraline (0.30% [−0.80, 1.40]) groups 
showed improvements, whereas the home-based exercise (−0.11% [−1.12, 0.90]) and 
placebo (−1.08% [−2.23, 0.07]) groups showed reductions in FMD (Table 2).
Intima Media Thickness—Participants in the exercise and sertraline groups exhibited 
lower post-treatment IMT compared with participants in the placebo group (P = .037). 
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Examination of IMT changes demonstrated that all groups experienced a small increase in 
IMT from pre- to post-treatment, although the progression of IMT was smaller in the active 
treatment groups. Home-based (0.02 mm [0.00, 0.05]) and supervised (0.02 mm [−0.01, 
0.04]) exercise groups exhibited small increases in IMT, whereas the IMT level for the 
sertraline group remained essentially unchanged (0.00 mm [−0.03, 0.02]); the placebo group 
exhibited a relatively greater progression post-treatment (0.04 mm [0.01, 0.07]).
In addition to the main effects of treatment, we observed a treatment group by baseline IMT 
interaction (P = .025). Examination of this interaction showed that individuals in the active 
treatment groups with higher levels of IMT at baseline experienced larger reductions in IMT 
over the course of the intervention; this pattern was especially pronounced in the exercise 
groups (Figure 2). We observed a moderate association between baseline IMT and changes 
in IMT from pre- to post-treatment in the exercise groups (r = −0.37, P < .001), suggesting 
that higher baseline IMT was associated with larger reductions with treatment. In contrast, 
baseline IMT was unrelated to treatment changes in the placebo group (r = 0.03, P = .876).
Exploratory analyses of changes in IMT among individuals with higher IMT at baseline (the 
highest quartile) revealed small IMT reductions in the home-based (−0.04 mm [−0.07, 0.03]) 
and supervised (−0.06 mm [−0.13, 0.01]) exercise groups, as well as the sertraline group 
(−0.02 mm [−0.07, 0.04]), whereas the placebo group exhibited a small increase in IMT 
(0.04 mm [−0.01, 0.10]).
Atherosclerotic Cardiovascular Disease (ASCVD) Risk Scores—Examination of 
changes in 10-year ASCVD risk revealed that individuals in the active treatment groups 
experienced greater reductions in ASCVD risk compared with placebo participants (P = .
049). Although the exercise and sertraline groups did not differ (P = .741), the supervised 
exercise group exhibited larger reductions in ASCVD risk compared to the other treatment 
groups, including home-based exercise (P = .010). Individuals in the supervised exercise 
group (0.57% [−0.01, 1.15]) and the sertraline (0.61% [0.01, 1.2]) groups showed larger 
reductions in CVD risk compared to the home-based (0.06% [−0.46, 0.59]) and the placebo 
(0.35% [−0.21, 0.92]) groups. The impact of treatment on CHD risk factors reported above 
corresponded to a small to moderate effect size difference between treatment groups and 
controls (d = 0.29).
Analysis of individual ASCVD components demonstrated that all treatment groups showed 
improvements in SBP relative to the placebo group (P = .033). Individuals in the supervised 
exercise (−6.0 mmHg [−10.1, −1.8]), home-base exercise (−2.4 mmHg [−6.4, 1.6]), and 
Sertraline group (−7.3 mmHg [−11.6, −2.2]) all exhibited reductions in SBP, whereas the 
placebo group exhibited a minimal increase in SBP (0.3 mmHg [−4.7, 4.1]). In contrast, the 
active treatment groups did not demonstrate improvements in HDL cholesterol (P = .545) or 
total cholesterol (P = .159). However, examination of pre-planned contrasts demonstrated 
that the Sertraline group exhibited a reduction in total cholesterol (P = .026) relative to the 
exercise groups, although the groups did not differ in post-treatment HDL (P = .772). The 
supervised and home-based exercise groups did not differ on any of the individual ASCVD 
components (Ps > .175).
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DISCUSSION
Our findings show that both exercise and sertraline are not only effective interventions for 
ameliorating symptoms of depression in patients with MDD (16), but also result in notable 
improvements in CHD risk factors. Overall, compared to placebo, both sertraline and 
exercise resulted in improved vascular endothelial function (brachial artery FMD), reduced 
progression of atherosclerosis (carotid IMT), and lowered the 10-year risk of developing 
atherosclerotic cardiovascular disease (AVSCD risk). Additionally, aerobic fitness improved 
significantly following treatment for participants randomized to both exercise conditions 
relative to the pill conditions, with supervised exercise enhancing aerobic fitness to a greater 
extent than home-based exercise.
Vascular endothelial dysfunction plays a vital role in the development, progression, and 
clinical manifestations of atherosclerosis (27–31). Therefore, improvements in FMD 
accompanying the successful treatment of depression could reduce patients’ CHD risk 
burden. However, the SADHART-CHF trial of patients with heart failure and MDD (13) did 
not demonstrate improved survival or reduced cardiovascular events in patients randomized 
to sertraline. The SADHART trial of patients with CHD and MDD (7) was not powered to 
evaluate the effects of treatment on clinical outcomes. Neither of the SADHART studies 
assessed FMD. Pooled data from clinical trials enrolling CHD patients participating in 
cardiac rehabilitation programs show that exercise reduces the risk of all-cause mortality and 
fatal CHD events by up to 25%. (32–35). To our knowledge, no studies have examined the 
extent to which improvements in FMD following exercise-based cardiac rehabilitation may 
contribute to more favorable clinical outcomes. The antidepressant effects of exercise 
training may also account for the survival benefits of cardiac rehabilitation for some 
patients. In a study of 522 consecutive coronary patients enrolled in cardiac rehabilitation, 
patients exhibited a 63% reduction in depressive symptoms following completion of the 
program, and depressed patients who completed the program had a 73% lower mortality 
than depressed patients who failed to complete the program. In a secondary analysis of the 
HF-ACTION trial (21), exercise training resulted in a reduction in depressive symptoms and 
improved clinical outcomes compared to usual care (19). It is possible that improved 
outcomes following exercise training are due, in part, to improvements in both depression 
and vascular function, as well as to other physiological and psychosocial benefits that may 
result from participation in cardiac rehabilitation.
Carotid IMT is a marker of atherosclerosis that is a strong predictor of CVD events, and is 
being used increasingly for CVD risk stratification; with a 0.1 mm increase in IMT the 
future risk of MI increases by 10% to 15%, and stroke risk increases by 13% to 18% (36). 
Our observations suggest that both exercise and sertraline may slow the progression of 
atherosclerosis, as indexed by changes in carotid artery IMT. To our knowledge, this is the 
first study to have reported beneficial effects of sertraline treatment on IMT, while the 
evidence of an association between exercise and IMT has been equivocal. Most cross-
sectional studies indicate increased IMT in regular exercisers (37), but interventional studies 
of exercise and IMT have been mixed (38). Interestingly, there is growing evidence that a 
reduction in arterial wall thickness may be more likely to result from exercise in individuals 
with pre-existing arterial wall thickening (39). Our finding that exercise resulted in 
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improvements in carotid IMT, especially in MDD patients with higher baseline IMT, is 
consistent with this more recent evidence. These data suggest that exercise may attenuate the 
progression of atherosclerosis especially among individuals with higher levels of subclinical 
atherosclerosis or with established CHD. In summary, these results suggest that SSRI 
antidepressant medication and exercise interventions are beneficial not only for reducing 
depressive symptoms, but also for reducing CHD risk factors. Moreover, our findings 
underscore the potential value of supervised exercise as a useful alternative approach to 
pharmacotherapy for treating patients with MDD, with both approaches potentially resulting 
in broader health benefits that may be especially helpful for patients at high ASCVD risk, or 
with documented CHD. Further research is needed to elucidate the mechanisms by which 
treatments for depression may yield both physical and mental health benefits, as well as 
improve clinical outcomes in cardiac patients.
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Figure 1. 
Pre-to-post-treatment changes in flow-mediated dilation (FMD) values by treatment group, 
adjusted for age, gender, severity of depression, baseline arterial diameter, and baseline 
FMD.
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Figure 2. 
Treatment changes by treatment group in Intima-Media Thickness (IMT) in relation to 
baseline IMT.
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